Source: Annual Congress 2004 - Targeting acute and chronic airway obstruction
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Travier, V. S Kocevar, D. D. Yin, L. Laforest, E. Van Ganse (Pierre-Bénite, France; Whitehouse Station, United States Of America). Cost of asthma rescue/acute and allergy medications among asthmatic patients on controller therapy. Eur Respir J 2004; 24: Suppl. 48, 2165

Member's Comments

No comment yet.

Related content which might interest you: Rescue/acute and allergy medication use among children on asthma controller therapy Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018 Year: 2018 Estimate of asthma control and adherence to inhaled corticosteroids in children with asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010 Adherence to inhaled controller therapy and local adverse events in children with asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Adherence with two types of inhaled corticosteroids as a primary controller regimen in adult asthma patients Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Control of persistent asthma patients on inhaled corticosteroids in a real-life setting Source: Annual Congress 2010 - New insights in the epidemiology of asthma Year: 2010 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Effect of allergic rhinitis on asthma-related hospitalization, GP visit and drug cost among adult asthmatic patients in the UK Source: Eur Respir J 2002; 20: Suppl. 38, 396s Year: 2002 Effect of asthma and asthma medication on the prognosis of patients with COVID-19 Source: Eur Respir J, 57 (3) 2002226; 10.1183/13993003.02226-2020 Year: 2021